Everything you need to know: information on tirzepatide for weight loss in the UK

You've read the headlines, here's what the tirzepatide information actually tells you

Most people arrive here after seeing a news story or a social-media post, usually with a figure like "20% body weight" attached. That figure is real, but context matters. The SURMOUNT-1 trial followed 2,539 adults with obesity over 72 weeks; participants on the 15 mg dose lost an average of around 20–21% of their starting body weight. That's a meaningful reduction. It's also a 72-week trial with a lifestyle programme alongside the medicine, not a standalone result from the injection alone.

Tirzepatide works by activating both the GIP receptor and the GLP-1 receptor. GLP-1 agonists have been around for some years, but adding GIP activity appears to amplify the appetite-suppression and metabolic effects. The result is slower gastric emptying (food stays in your stomach longer, so you feel full sooner) and reduced hunger signals in the brain. For many people this makes it easier to eat less without the constant mental effort that characterises most calorie-deficit diets.

It is sold in the UK under the brand name Mounjaro, made by Eli Lilly, and you can find a full breakdown of how the medicine works on our Mounjaro information page. Each pen contains four weekly doses; you inject once a week into your abdomen, thigh or upper arm, rotating the site. The pen is pre-filled and pre-set, you don't draw up a dose. If that mechanical side of things worries you, our patient information guide for Mounjaro walks through the injection process in plain language.

One thing the tirzepatide information trail often skips: this is a Black Triangle (▼) medicine, meaning the MHRA wants extra post-market data while it's relatively new. That's a standard designation for recently licensed products, not a signal of unusual danger, but it does mean your prescriber and the regulator are watching the evidence base as it builds.

Who the licence actually covers, and where the NHS thresholds sit

The licensed eligibility for private prescription broadly follows the medicine's Summary of Product Characteristics: adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. BMI alone isn't the whole picture; a prescriber reviews your medical history, current medicines and any contraindications before deciding whether to prescribe.

NICE's technology appraisal (TA1026, published December 2024) sets different thresholds for NHS access: a BMI of 35 or above, plus at least one weight-related comorbidity. For people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, those thresholds are reduced by 2.5 kg/m² throughout. The NICE TA1026 recommendations also specify that if someone loses less than 5% of their body weight after six months at the highest tolerated dose, continuing treatment should be reviewed.

NHS rollout is phased and strict. From around June 2026, Cohort 2 covers people with a BMI of 35–39.9 plus four or more qualifying conditions. GP practices may prescribe under the 2026/27 contract, but participation varies by practice. Waiting lists exist. For people who don't meet the current NHS criteria or who don't want to wait, a private prescription through a regulated pharmacy is the legal alternative, provided a prescriber confirms suitability after a proper assessment.

Some people ask whether they can transfer from another private clinic. That's possible, but any pharmacy should ask to see evidence of your current dose and treatment history before continuing or increasing your prescription. Be wary of any provider that doesn't.

Side effects worth knowing about before you start

The most common side effects are gastrointestinal: nausea, loose stools, constipation, bloating, indigestion and, for some people, vomiting. These typically peak after starting or after a dose increase, and they often ease within a week or two as the body adjusts. Starting at 2.5 mg exists precisely for this reason, the first pen's job is settling your system, not delivering full therapeutic effect.

Pancreatitis is a less common but more serious risk. In January 2026 the MHRA issued a Drug Safety Update specifically addressing acute pancreatitis with GLP-1 medicines: severe, persistent abdominal pain that radiates to the back, with or without vomiting, needs urgent medical attention. That guidance is worth reading if you're researching side effects in depth. You can find the full safety communications index at the MHRA Yellow Card site, where you can also report any side effect you experience.

Other things to flag to your prescriber: if you use the oral contraceptive pill, current guidance advises adding a barrier method for the first four weeks of tirzepatide treatment and for four weeks after each dose increase, because absorption of the pill may be reduced. If you're on HRT, transdermal preparations (patches or gels) may be preferable for the same reason. Discuss both with whoever is prescribing for you.

Tirzepatide is not licensed for under-18s, and our tirzepatide page covers the full eligibility criteria and contraindications in detail. It isn't recommended during pregnancy, breastfeeding, or for anyone actively trying to conceive. Certain conditions, including a personal or family history of medullary thyroid carcinoma, require a detailed prescriber discussion before any GLP-1 medicine is considered.

Private access through a regulated pharmacy: what to look for

If you're considering a private prescription, the first check is whether the pharmacy is registered with the GPhC. You can look up any pharmacy at the GPhC pharmacy register; nume's premises registration number is 9012878. That's the minimum bar. Beyond registration, ask how the clinical review works: a consultation that results in a prescription without a real prescriber reading your answers is a red flag, regardless of the price.

Speaking of price: Eli Lilly raised Mounjaro's UK list price from September 2025, and private market prices now typically range from around £149 to £375 per month depending on dose and provider. The lowest quote doesn't help you if it comes without proper clinical oversight. If you want to understand how pricing compares and what's typically included or excluded, the Mounjaro cost guide sets this out plainly.

At nume, medicines are dispensed through our own GPhC-registered pharmacy, sourced through the licensed UK supply chain. Every consultation is personally reviewed by a GPhC-registered Independent Prescriber. If you order before 12pm on a working day (even if that's a Monday morning before the week bites) treatment that is clinically approved is dispatched the same day and delivered by DPD the next working day, tracked and in plain packaging. There are no subscriptions and no auto-renewals; every repeat order is reviewed again before anything is sent.

If you'd like to talk through whether tirzepatide is appropriate for your situation, speak to our prescribers through a free consultation. You can also read more about the wider treatment landscape on our weight loss overview, explore the Mounjaro treatment page for specifics on the brand, or see the tirzepatide L page for information on the higher-dose options.